Report Overview

The South Korea Mucopolysaccharidosis treatment market size stood at around USD xx billion in 2020 and is projected to reach xx billion by 2028, exhibiting a CAGR of around xx% during the forecast period.

Mucopolysaccharidoses (MPSs) are a group of inherited metabolic diseases, which are a result of deficiencies in specific lysosomal enzymes that are required for the degradation of glycosaminoglycans (GAGs). It is known that there are eleven genes are causally related to MPS. Deficiency in a specific enzyme results in the accumulation of undegraded GAGs, which causes progressive damage to cells, tissues, and organs. MPS has a broad spectrum of clinical presentations with varied severity and prognosis for different types and individuals. MPS disorders are autosomal recessive, except for MPS II (Hunter syndrome), which has Xlinked inheritance and mainly affects males.

The prevalence of MPS in South Korea population is around 1.35 per 100,000. MPS II is the most prevalent type of MPS (54.6%), followed by MPS III (18.4%), MPS I (15.3%), MPS IV (9.5%), and MPS VI (1.4%).



Market Drivers

The lack of presence of wide range of therapeutics for the patients has led to the domination of enzyme replacement therapy. For instance, Elaprase is the most commonly and widely used drug for mucopolysaccharidosis type II (Hunter Syndrome). Expected launch of cheaper alternatives and advanced therapeutics is likely to drive the growth of South Koreas MPS treatment market. There are a significant number of pipeline candidates for the development of advanced therapeutics for various types of MPS by global players, this will further propel the market drive. High cost of therapeutics along with poor diagnosis rates restrain the market growth.